MESOBIOTIX PRESS

Patent Name: RegenoCyte Complex X7 (RCX7®) - Mesobiotix

Compound Description: RCX7® is a pioneering innovation from Mesobiotix, led by Dr. Lara Schilling, a renowned expert and key figure in aesthetic medicine. This compound represents the pinnacle of more than two decades of international research and experience, encapsulating the philosophy of "aesthetic medicine with conscience."

Active principles:

• Proteins: More than 3,000 biomimetic proteins designed to mimic and enhance the skin's natural regenerative functions.

• Growth Factors: A diverse range of growth factors, including EGF, FGF and VEGF, to stimulate cell repair and renewal.

• Cytokines: Cytokines selected to optimize cellular communication and accelerate skin tissue regeneration.

• Exosomes: Microvesicles that facilitate the transfer of signaling molecules between cells, improving the effectiveness of the active ingredients.

Benefits and Applications:

• Increased Production of Elastin and Hyaluronic Acid: Contributes to greater elasticity and hydration of the skin, visibly reducing wrinkles and fine lines.

• Stimulation of Hair Follicular Cells: Promotes healthy hair growth and combats hair loss.

• Reduction of Scalp Inflammation: Relieves symptoms of scalp irritation and sensitivity.

• Deep Penetration: RCX7® reaches the deepest layers of the skin, ensuring a comprehensive regenerative action.

Safety and Efficacy: As leader of EOne Clinic and founder of EOne Médica Institute, and CEO of Mesobiotix Cosmeceutical, Dr. Schilling has ensured that RCX7® meets the highest standards of quality and safety, reflecting her commitment to treatments and products that They not only beautify, but also protect and nourish the skin.

Innovation and Consciousness: This compound is the result of a collaborative effort that unites advanced science, technological innovation and an ethical approach in aesthetic medicine. RCX7® is a testament to Dr. Schilling's leadership in promoting responsible and conscious aesthetic medicine.